Josie Hayes

Josie Hayes

Auto-generated profile, based on publicly available information

Josie Hayes

UC Berkeley

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
JHJosie Hayes
Josie Hayes
PPPier Paolo Peruzzi
Pier Paolo Peruzzi
SLSean Lawler
Sean Lawler

2 March 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
FRFranz Ricklefs
Franz Ricklefs
QAQuazim Alayo
Quazim Alayo
HKHarald Krenzlin
Harald Krenzlin
AMAhmad B. Mahmoud
Ahmad B. Mahmoud
MSMaria C. Speranza
Maria C. Speranza
ACAntonio Chiocca
Antonio Chiocca
Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cancer immune evasion via inhibition of T cell function. One of the defining characteristics of glioblastoma, a universally fatal brain cancer, is its profound local and systemic immunosuppression. Glioblastoma has also been shown to generate extracellular vesicles (EVs), which may play an important role in tumor progression. We thus hypothesized that glioblastoma EVs may be important mediators of immunosuppression and that PD-L1 could play a role. We show that glioblastoma EVs block T cell activation and proliferation in response to T cell receptor stimulation. PD-L1 was expressed on the surface of some, but not of all, glioblastoma-derived EVs, with the potential to directly bind to PD1. An anti-PD1 receptor blocking antibody significantly reversed the EV-mediated blockade of T cell activation but only when PD-L1 was present on EVs. When glioblastoma PD-L1 was up-regulated by IFN-γ, EVs also showed some PD-L1–dependent inhibition of T cell activation. PD-L1 expression correlated with the mesenchymal transcriptome profile and was anatomically localized in the perinecrotic and pseudopalisading niche of human glioblastoma specimens. PD-L1 DNA was present in circulating EVs from glioblastoma patients where it correlated with tumor volumes of up to 60 cm3. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.

1 September 2013 in Genomics
Verified
Journal Article
Closed access
JHJ.L. Hayes
J.L. Hayes
ATA. Tzika
A. Tzika
HTH. Thygesen
H. Thygesen
SBS. Berri
S. Berri
HWHenry M Wood
Henry M Wood
GTG.R. Taylor
G.R. Taylor

1 July 2016 in Molecular Oncology
Verified
Journal Article
Open access
JHJosie Hayes
Josie Hayes
HTHelene Thygesen
Helene Thygesen
WGWalter Gregory
Walter Gregory
DWDavid R. Westhead
David R. Westhead
PFPim French
Pim French
SSSusan C Short
Susan C Short
Purpose: We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients.Patients and methods: TCGA microRNA expression data from tumors resected at first diagnosis of glioblastoma in patients treated with bevacizumab at any time during the course of their disease were randomly separated into training (n = 50) and test (n = 37) groups for model generation. MicroRNA‐seq data for 51 patients whose treatment included bevacizumab in the BELOB trial were used as an independent validation cohort.Results: Using penalized regression we identified 8 microRNAs as potential predictors of overall survival in the training set. We dichotomized the response score based on the most prognostic minimum of a density plot of the response scores (log‐rank HR = 0.16, p = 1.2e−5) and validated the profile in the test cohort (one‐sided log‐rank HR = 0.34, p = 0.026). Analysis of the profile using all samples in the TCGA glioblastoma dataset, regardless of treatment received, (n = 473) showed that the prediction of patient benefit was not significant (HR = 0.84, p = 0.083) suggesting the profile is specific to bevacizumab. Further independent validation of our microRNA profile in RNA‐seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043).Conclusion: We have identified and validated an 8‐microRNA profile that predicts overall survival in patients with glioblastoma treated with bevacizumab. This may be useful for identifying patients who are likely to benefit from this agent.

26 December 2014 in Oncoscience
Verified
Journal Article
Open access
JHJosie Hayes
Josie Hayes
HTHelene Thygesen
Helene Thygesen
ADAlastair Droop
Alastair Droop
THThomas Hughes
Thomas Hughes
DWDavid Westhead
David Westhead
SSSusan C Short
Susan C Short
MicroRNA expression can be exploited to define tumor prognosis and stratification for precision medicine. It remains unclear whether prognostic microRNA signatures are exclusively tumor grade and/or molecular subtype-specific, or whether common signatures of aggressive clinical behavior can be identified. Here, we defined microRNAs that are associated with good and poor prognosis in grade III and IV gliomas using data from The Cancer Genome Atlas. Pathway analysis of microRNA targets that are differentially expressed in good and poor prognosis glioma identified a link to oligodendrocyte development. Notably, a microRNA expression profile that is characteristic of a specific oligodendrocyte precursor cell type (OP1) correlates with microRNA expression from 597 of these tumors and is consistently associated with poor patient outcome in grade III and IV gliomas. Our study reveals grade-independent and subtype-independent prognostic molecular signatures in high-grade glioma and provides a framework for investigating the mechanisms of brain tumor aggressiveness.

22 May 2018 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
WEWilliam M B Edmands
William M B Edmands
JHJosie Hayes
Josie Hayes
SRStephen M Rappaport
Stephen M Rappaport
Liquid chromatography mass spectrometry (LC-MS) is the favored method for untargeted metabolomic analysis of small molecules in biofluids. Here we present SimExTargId, an open-source R package for autonomous analysis of metabolomic data and real-time observation of experimental runs. This simultaneous, fully automated and multi-threaded (optional) package is a wrapper for vendor-independent format conversion (ProteoWizard), xcms- and CAMERA- based peak-picking, MetMSLine-based pre-processing and covariate-based statistical analysis. Users are notified of detrimental instrument drift or errors by email. Also included are two shiny applications, targetId for real-time MS2 target identification, and peakMonitor to monitor targeted metabolites. SimExTargId is publicly available under GNU LGPL v3.0 license at https://github.com/JosieLHayes/simExTargId, which includes a vignette with example data. SimExTargId should be installed on a dedicated data-processing workstation or server that is networked to the LC-MS platform to facilitate MS1 profiling of metabolomic data. Supplementary data are available at Bioinformatics online.